Holen Sie sich die Stockscreener-App
4.04
5.39%
-0.23
Handel nachbörslich:
4.01
-0.03
-0.74%
Schlusskurs vom Vortag:
$4.27
Offen:
$4.29
24-Stunden-Volumen:
92,631
Relative Volume:
1.22
Marktkapitalisierung:
$320.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.50M
KGV:
-15.60
EPS:
-0.259
Netto-Cashflow:
$-11.89M
1W Leistung:
-3.35%
1M Leistung:
+5.48%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.98
$4.3649
1-Wochen-Bereich:
$3.80
$4.39
52-Wochen-Spanne:
$3.73
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Firmenname
Nervgen Pharma Corp
Sektor
Branche
Telefon
-
Adresse
-
Compare NGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
4.04 | 338.24M | 0 | -18.50M | -11.89M | -0.259 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nervgen Pharma Corp Aktie (NGEN) Neueste Nachrichten
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel - TipRanks
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP - TipRanks
NervGen appoints regulatory and patient advocacy executives - Investing.com Nigeria
NervGen appoints regulatory and patient advocacy executives By Investing.com - Investing.com Australia
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs - The Manila Times
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma to Participate at Upcoming Investor Conferences - The Manila Times
How NervGen Pharma Corp. (9UA) stock reacts to weak economy2025 Dividend Review & Low Risk High Win Rate Picks - mfd.ru
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - The Manila Times
NervGen Pharma appoints Dr. Adam Rogers as CEO and president By Investing.com - Investing.com Nigeria
Why NervGen Pharma Corp. (9UA) stock stays on buy listsInsider Selling & High Conviction Investment Ideas - mfd.ru
Why NervGen Pharma Corp. (9UA) stock could be next leader2025 Price Momentum & Growth Focused Stock Pick Reports - mfd.ru
NervGen Pharma to Present at Unite2Fight Paralysis 20th Annual Science and Advocacy Symposium - marketscreener.com
NervGen Pharma Corp. Announces CFO Changes, Effective March 15, 2026 - marketscreener.com
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium - The Manila Times
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - MSN
NervGen Pharma appoints new president & CEO - MSN
NervGen Pharma appoints Dr. Adam Rogers as CEO and president - Investing.com
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal - TipRanks
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury - marketscreener.com
NervGen Pharma names Adam Rogers as CEO - The Pharma Letter
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase - TipRanks
NervGen appoints Rogers as CEO to lead neuroreparative drug development By Investing.com - Investing.com Australia
NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase - TipRanks
NervGen Pharma Appoints New CEO Adam Rogers - Intellectia AI
Adam Rogers Appointed CEO of NervGen Pharma to Advance Spinal Cord Injury Treatment Efforts - geneonline.com
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291 - GuruFocus
NervGen Pharma Names Adam Rogers as CEO - marketscreener.com
NervGen appoints Rogers as CEO to lead neuroreparative drug development - Investing.com
NervGen Pharma Corp appoints Adam Rogers as chief executive officer - marketscreener.com
NervGen Pharma Corp. Appoints Adam Rogers as Chief Executive Officer, Effective February 9, 2026 - marketscreener.com
New drug may help spinal cord injury patients regain function and hope - WGN-TV
When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven? - Yahoo Finance
Johnson & Johnson receives CHMP positive opinion for AKEEGA - marketscreener.com
Analysts Expect Breakeven For NervGen Pharma Corp. (CVE:NGEN) Before Long - simplywall.st
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
NervGen Pharma Rings the Closing Bell - Nasdaq
NervGen Pharma Rings the Nasdaq Stock Market Closing Bell - Nasdaq
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing - GlobeNewswire
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment - MSN
symbol__ Stock Quote Price and Forecast - CNN
NervGen Pharma Begins Trading on Nasdaq Today - Sahm
Is NervGen Pharma Corp. (9UA) stock good for wealth creationJuly 2025 Movers & Weekly High Conviction Trade Ideas - Улправда
NervGen Pharma Debuts On Nasdaq - Nasdaq
Finanzdaten der Nervgen Pharma Corp-Aktie (NGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):